Jun 26, 2023 · Eli Lilly’s Mounjaro, cleared for type 2 diabetes and awaiting FDA approval for weight loss, targets both GLP-1 and a hormone called GIP, and has produced weight loss of 21 to 23%.

Feb 6, 2025 · Eli Lilly and Company (NYSE: LLY) has announced that it will release late-stage data on its next-generation weight loss drug, retatrutide, in 2025, earlier than initially expected.

Aug 27, 2024 · Starter doses of the weight-loss drug Zepbound are now available in single-dose vials, drug manufacturer Eli Lilly announced Tuesday, a move the company says will “significantly” expand supply...

Nov 8, 2023 · Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight.

Jun 23, 2023 · Eli Lilly’s experimental pill for weight loss helped people lose an average of 15% of their body weight after 36 weeks on the highest dose in a midstage trial, rivaling what’s seen with...

Jun 27, 2023 · Drug manufacturer Eli Lilly also recently released phase 2 clinical trial results for its weight loss pill, orforglipron, in people with obesity or who were overweight but did not have Type 2...

Nov 9, 2023 · Here’s what you need to know about Lilly’s new drug. How well does Zepbound work? The active ingredient in Zepbound is tirzepatide, which mimics a hormone that helps reduce food cravings.

Jan 26, 2025 · Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as effective as bariatric surgery.

Nov 14, 2023 · The FDA recently approved a new Eli Lilly drug, Zepbound (tirzepatide), for chronic weight management in adults with at least one weight-related health condition.

Jan 1, 2023 · In 2023, the FDA will likely approve Eli Lilly's diabetes drug tirzepatide for weight loss — but there's little indication insurers will widely cover the medication. A new class of injectable...